D.E. Shaw & Co
NAMS icon

D.E. Shaw & Co’s NewAmsterdam Pharma NAMS Stock Holding History

D.E. Shaw & Co’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09M Buy
+120,561
New +$3.97M ﹤0.01% 2578
2024
Q4 		– Sell
-18,345
Closed -$305K – 4710
2024
Q3 		$305K Buy
+18,345
New +$317K ﹤0.01% 3968

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

D.E. Shaw & Co's NAMS Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 120,561 shares worth $4.09M. The stake represents ﹤0.01% of the portfolio and ranks #2578 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in NAMS as recently as Q3 2024.

D.E. Shaw & Co first reported a position in NAMS in Q3 2024 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • D.E. Shaw & Co held 120,561 shares of NewAmsterdam Pharma worth $4.09M as of Q2 2026.
  • NewAmsterdam Pharma was a new D.E. Shaw & Co position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2578 holding.
  • D.E. Shaw & Co first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.